Catriona Yale - Mar 10, 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Development Officer
Signature
/s/ Jonathan Young, Attorney-in-fact
Stock symbol
AKRO
Transactions as of
Mar 10, 2023
Transactions value $
-$30,465
Form type
4
Date filed
3/14/2023, 04:20 PM
Previous filing
Jan 18, 2023
Next filing
Jun 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Tax liability -$30.5K -701 -0.86% $43.46 80.6K Mar 10, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units.